Item no. |
HY-N0607-25mg |
Manufacturer |
MedChem Express
|
CASRN |
34367-04-9 |
Amount |
25 mg |
Quantity options |
10 mM/1 mL
10 mg
25 mg
50 mg
5 mg
|
Specific against |
other |
Purity |
99.81 |
Citations |
[1]Kwon HW, et al. Inhibitory Effects of Cytosolic Ca<sup>2+</sup> Concentration by Ginsenoside Ro Are Dependent on Phosphorylation of IP3RI and Dephosphorylation of ERK in Human Platelets. Evid Based Complement Alternat Med. 2015;2015:764906. [2]Jung-HaeShin, et al. Inhibitory effects of thromboxane A2 generation by ginsenoside Ro due to attenuation of cytosolic phospholipase A2 phosphorylation and arachidonic acid release. J Ginseng Res. 9 Jan 2018. [3]Kim S, et al. Upregulation of heme oxygenase-1 by ginsenoside Ro attenuates lipopolysaccharide-induced inflammation in macrophage cells. J Ginseng Res. 2015 Oct;39(4):365-70. [4]Jiang Z, et al. The traditional Chinese medicine Achyranthes bidentata and our de novo conception of its metastatic chemoprevention: from phytochemistry to pharmacology. Sci Rep. 2017 Jun 20;7(1):3888. |
Smiles |
O=C([C@]1(CCC(C)(C)C2)[C@]2([H])C3=CC[C@@]4([H])[C@@](C)(CC[C@]5([H])[C@@]4(CC[C@H](O[C@@](O[C@H](C(O)=O)[C@@H](O)[C@@H]6O)([H])[C@@H]6O[C@]([C@@H]([C@@H](O)[C@@H]7O)O)([H])O[C@@H]7CO)C5(C)C)C)[C@]3(C)CC1)O[C@@H]([C@@H]([C@@H](O)[C@@H]8O)O)O[C@@H]8CO |
Alias |
Polysciasaponin P3, Chikusetsusaponin 5, Chikusetsusaponin V |
Shipping condition |
Room temperature |
Available |
|
Manufacturer - Type |
Natural Products |
Manufacturer - Applications |
COVID-19-immunoregulation |
Manufacturer - Targets |
Calcium Channel; Prostaglandin Receptor |
Shipping Temperature |
Room Temperature |
Storage Conditions |
-20°C, 3 years; 4°C, 2 years (Powder) |
Product Description |
Ginsenoside Ro (Polysciasaponin P3; Chikusetsusaponin 5; Chikusetsusaponin V) exhibits a Ca2+-antagonistic antiplatelet effect with an IC50 of 155 ?μM. Ginsenoside Ro reduces the production of TXA2 more than it reduces the activities of COX-1 and TXAS. |
Manufacturer - Research Area |
Cardiovascular Disease; Endocrinology |
Solubility |
DMSO : 100 mg/mL (ultrasonic) |
Manufacturer - Pathway |
GPCR/G Protein; Membrane Transporter/Ion Channel; Neuronal Signaling |
Isoform |
Calcium Channel; TXA2/TP |
Clinical information |
No Development Reported |
Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.
All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.